(VIANEWS) – Shares of ERYTECH PHARMA (CAC 40: ERYP.PA) jumped by a staggering 12.52% to €0.89 at 13:59 EST on Thursday, after two sequential sessions in a row of gains. CAC 40 is falling 0.51% to €7,094.54, after three successive sessions in a row of gains. This seems, up until now, a somewhat negative trend trading session today.
ERYTECH PHARMA’s last close was €0.80, 64.82% under its 52-week high of €2.26.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-1.14.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ERYTECH PHARMA’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth declined by 58.5%, now sitting on 2.2M for the twelve trailing months.
Volume
Today’s last reported volume for ERYTECH PHARMA is 893342 which is 34.07% above its average volume of 666276.
Volatility
ERYTECH PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 4.07%, a negative 0.65%, and a positive 6.09%.
ERYTECH PHARMA’s highest amplitude of average volatility was 4.82% (last week), 5.02% (last month), and 6.09% (last quarter).
More news about ERYTECH PHARMA (ERYP.PA).
